PA 542 Final exam - Puzzle 1

Edit Answers
12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455
Across
  1. 3. A hemodynamically-mediated kidney injury associated with ACEI
  2. 8. A strategy used to manage volume and salt intake in many fluid/electrolyte disorders (hint: verb)
  3. 9. Depolarizing neuromuscular blocker causing muscle fasciculations
  4. 11. Phosphate binder with no impact on calcium levels
  5. 15. part of someone’s social history you need to know about when prescribing an oral combination contraceptive
  6. 16. this needs to be corrected before SGLT2-inhibitors can be given
  7. 18. Dosage forms include subcutaneous, nasal powder, nasal spray, oral short-acting tablets, and oral long-acting tablets (Generic name)
  8. 21. The neurotransmitter that is deficient in patients with cognitive impairment
  9. 23. Used for the treatment of both tension and migraine headaches
  10. 26. a common GI toxicity associated with alkylating agents
  11. 28. a word used to describe a pain management modality that is added to a pain regimen
  12. 29. A medication for MS that must be monitored for at least 6 hours in patients with history of heart issues
  13. 31. The antiemetic limited to no more than 12 continuous weeks of continual use
  14. 35. The fluid balance hormone
  15. 36. celecoxib is associated with a high risk of adverse effects to this organ
  16. 37. pioglitazone results in fluid retention that leads to this adverse effect
  17. 38. The receptor type that succinylcholine agonizes
  18. 43. a term used to describe a MAB attached to another medication, toxic, or radioactive particle
  19. 44. A lab that should be monitored when on long-term propofol therapy
  20. 47. a toxicity associated with cyclophosphamide due to acrolein metabolite (2 words)
  21. 49. A medication class commonly associated with causing constipation
  22. 50. a benzodiazepine that should be avoided with concomitant opioid use
  23. 51. May decrease the effectiveness of oral contraceptives
  24. 52. The safest medication for a pregnancy patient with MS
  25. 53. an RA treatment that must be given in combination with methotrexate
  26. 54. The relationship between SCr and creatinine clearance
  27. 55. a medication for RA with a 2-year elimination rate
Down
  1. 1. Triptans are contraindicated with what uncontrolled disease state
  2. 2. A medication for PD that requires an antiemetic be given prior to administration
  3. 4. An anticonvulsant that has a narrow therapeutic index
  4. 5. the antimetabolite chemotherapy agent used in colorectal regimens such as FOLFOX
  5. 6. A non-depolarizing NMBA with an intermediate onset and duration of action
  6. 7. the vinca alkaloids are also known by this term due to the potential for extravasation
  7. 10. an electrolyte elevated in kidney disease with difficulty-to-adhere to dietary restrictions
  8. 12. a term used to describe the need for increasing doses of opioids
  9. 13. type of headache pain that is accompanied with nausea and visual changes
  10. 14. A medication for PD with an FDA-approved indication for use as monotherapy
  11. 17. Respiratory depression that can be severe is associated with use of this anticonvulsant
  12. 19. a type of immunotherapy created for a specific purpose
  13. 20. The most effective medication for use in PD
  14. 22. a medication associated with hypoglycemia risk especially in elderly
  15. 24. how to describe a person who has not received an opioid for the past 7 days straight
  16. 25. a contraindication to many anti-resorptive therapies
  17. 27. a black box warning associated with SGLT2-inhibitors
  18. 30. A nickname for the medication class used to treat SIADH associated with euvolemic hyponatremia
  19. 32. A drug-related risk factor associated with acute kidney injury
  20. 33. The word to describe the type of medication release often avoided in ESRD
  21. 34. A sedative associated with PRIS
  22. 39. a medication used to accelerate neutrophil recovery in a patient with neutropenia due to chemotherapy
  23. 40. HLA-B* 15:02 testing is required for high-risk patients receiving this medication for seizures
  24. 41. PD-1 inhibitors and PD-L1 inhibitors can also be described as _____________ inhibitors
  25. 42. a medication that inhibits dipeptidyl peptidase-4
  26. 45. The type of change to weight associated with topiramate therapy
  27. 46. A non-depolarizing NMBA with an intermediate onset and duration of action
  28. 48. the gene that must be tested prior to a patient receiving 6-mercaptuoprine therapy for cancer